Eton Pharmaceuticals Cost of Revenue | ETON

Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.

What is included in the cost of revenue

Cost Category	Examples
Production Costs	Materials, wages of production staff, depreciation of equipment
Service and Support	Customer service, user support, technical assistance
Delivery and Logistics	Packaging, delivery of goods to customers
Hosting and Infrastructure	Servers, cloud platforms (especially for IT and SaaS companies)
Content and Licenses	License purchases, production royalties (e.g., in streaming services)

Importance of the Metric

Helps to understand how costly the revenue-generating process is.
A high cost of revenue may indicate:
Poor cost control
Low operational efficiency
A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.

Annual Cost of Revenue Eton Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
37.2 M	15.6 M	10.6 M	6.93 M	2.83 M	436 K	453 K	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
37.2 M	436 K	10.6 M

Quarterly Cost of Revenue Eton Pharmaceuticals

2026-Q2	2026-Q1	2025-Q4	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
7 M	9.53 M	-	14.6 M	7 M	7.42 M	-	4.02 M	3.45 M	2.96 M	-	2.62 M	2.32 M	1.96 M	-	1.2 M	2.74 M	849 K	-	654 K	174 K	1.59 M	-	144 K	28 K	102 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
14.6 M	28 K	3.52 M

Cost of Revenue of other stocks in the Biotechnology industry

Issuer	Cost of Revenue	Price	% 24h	Market Cap	Country
Qilian International Holding Group Limited QLI	31.6 M	-	-6.08 %	$ 184 M	China
Happiness Biotech Group Limited HAPP	62.5 K	-	1.35 %	$ 17.8 M	China
Dynavax Technologies Corporation DVAX	49.4 M	-	-	$ 2.02 B	USA
BioXcel Therapeutics BTAI	164 K	$ 1.19	5.31 %	$ 14.5 M	USA
Burford Capital Limited BUR	43.6 M	$ 4.37	0.23 %	$ 958 M	Britain
I-Mab IMAB	27.2 M	-	-	$ 866 M	China
BeyondSpring BYSI	3.2 M	$ 0.84	34.27 %	$ 34.5 M	USA
AgeX Therapeutics AGE	40 K	-	-10.17 %	$ 12.2 K	USA
Cerus Corporation CERS	33.4 M	$ 2.98	4.93 %	$ 568 M	USA
Compugen Ltd. CGEN	9.25 M	$ 2.41	4.17 %	$ 225 M	Israel
CureVac N.V. CVAC	106 M	-	-	$ 867 M	Germany
Abcam plc ABCM	91.2 M	-	-	$ 4.9 B	Britain
Midatech Pharma plc MTP	926 K	-	-18.52 %	$ 27.3 M	Britain
MorphoSys AG MOR	58.4 M	-	2.43 %	$ 254 M	Germany
Champions Oncology CSBR	30.9 M	$ 5.1	2.63 %	$ 70.5 M	USA
AnPac Bio-Medical Science Co., Ltd. ANPC	3.71 M	-	-1.58 %	$ 28.1 M	China
Celyad Oncology SA CYAD	515 K	-	-	$ 12.5 M	Belgium
Anika Therapeutics ANIK	49 M	$ 21.5	1.56 %	$ 308 M	USA
Aurinia Pharmaceuticals AUPH	32.7 M	$ 15.47	1.91 %	$ 2.08 B	Canada
Aeterna Zentaris AEZS	4.85 M	-	5.93 %	$ 314 M	Canada
BeiGene, Ltd. BGNE	286 M	-	0.49 %	$ 251 B	Cayman-islands
AIkido Pharma AIKI	145 M	-	1.93 %	$ 17.4 M	USA
BioMarin Pharmaceutical BMRN	717 M	$ 67.36	0.99 %	$ 12.9 B	USA